Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
March 27, 2024
Today marks a significant milestone as the Bill & Melinda Gates Foundation (BMGF) announces a new Open Access policy, representing a departure from traditional practices. This policy will cease support for individual article publishing fees, known as APCs, and mandate the use of preprints while advo...
Blog Post
November 30, 2023
The latest climate COP, or “Conference of the Parties to the United Nations Framework Convention on Climate Change,” got underway today in Dubai. It will be attended by thousands of delegates from governments, the private sector, media, and civil society, with two hectic weeks of events and negotiat...
Blog Post
November 28, 2023
Recent news that developed countries may finally have delivered on their promise to mobilise $100 billion of climate finance is welcome. But it is nowhere near enough to meet the aims of the Paris Agreement, and climate finance will continue to be an extremely contentious issue at COP28 in Dubai. So...
Blog Post
November 01, 2023
With just a month to go before COP28, the question of climate finance is threatening to derail the negotiations. Failure to deliver on past promises have damaged trust, and current discussions around both the New Collective Quantified Goal (NCQG) and especially the promised Loss and Damage (L&D) Fun...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...